Fast-acting human insulin - Adocia
Alternative Names: BC-222 human insulin; BioChaperone 222; BioChaperone® Human Insulin; BioChaperone® rhInsulin; HinsBet; Hinsbet-U500; HinsBet® U100; Rapid-acting human insulin - AdociaLatest Information Update: 21 Jan 2022
Price :
$50 *
At a glance
- Originator Adocia
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Diabetes mellitus
Highest Development Phases
- Phase II Type 1 diabetes mellitus
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in France (SC)
- 01 Oct 2018 Adverse events and pharmacokinetics data from a clinical trial in Healthy volunteers presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
- 01 Oct 2018 Adocia initiates enrolment in a clinical trial in Healthy volunteers before October 2018